Harv Rev Psychiatry 2022 May 26. Epub 2022 May 26.
From Harvard Medical School; Department of Psychiatry (Drs. Koire and Joffe), Connors Center for Women's Health and Gender Biology (Dr. Joffe), and Center for Alzheimer Research and Treatment, Department of Neurology (Dr. Buckley), Brigham and Women's Hospital, Boston, MA; Department of Neurology, Massachusetts General Hospital, Boston, MA (Dr. Buckley); Melbourne School of Psychological Science and Florey Institutes, University of Melbourne (Dr. Buckley).
Abstract: Menopause has been associated with subjective cognitive dysfunction and elevated rates of depression. While menopausal hormone therapy (MHT) is Food and Drug Administration-approved for the treatment of vasomotor symptoms related to menopause, a potential role for MHT in treating and preventing cognitive decline, dysfunction, and dementia has remained unclear and a topic of continued interest and debate across decades of research. Increasing numbers of patients are seeking help for subjective cognitive decline, and those with poorer mental health are substantially more likely to perceive themselves to be at high risk of developing dementia; thus, mental health professionals are likely to encounter such patients and may be asked to provide advice concerning MHT, cognition, and indications for MHT use. Read More